No PriorsNo Priors Ep. 116 | With Sarah and Elad
Sarah Guo on aI Markets Crystallize As Founders Face Consolidation And New Frontiers.
In this episode of No Priors, featuring Sarah Guo and Elad Gil, No Priors Ep. 116 | With Sarah and Elad explores aI Markets Crystallize As Founders Face Consolidation And New Frontiers Sarah and Elad discuss how parts of the AI market are finally consolidating, with clearer early winners emerging in areas like coding assistants, customer success, and healthcare applications. They contrast these with still-open arenas such as sales, finance, accounting, and pharma, where the right product approach or model capabilities have yet to fully materialize. Elad argues that startup–startup mergers will increasingly be rational to better fight entrenched incumbents, while Sarah highlights cultural and status barriers to such moves. The conversation then pivots to under-explored biotech opportunities and to AI research frontiers like world models and reinforcement learning as pathways toward more capable agents and eventual AGI.
At a glance
WHAT IT’S REALLY ABOUT
AI Markets Crystallize As Founders Face Consolidation And New Frontiers
- Sarah and Elad discuss how parts of the AI market are finally consolidating, with clearer early winners emerging in areas like coding assistants, customer success, and healthcare applications. They contrast these with still-open arenas such as sales, finance, accounting, and pharma, where the right product approach or model capabilities have yet to fully materialize. Elad argues that startup–startup mergers will increasingly be rational to better fight entrenched incumbents, while Sarah highlights cultural and status barriers to such moves. The conversation then pivots to under-explored biotech opportunities and to AI research frontiers like world models and reinforcement learning as pathways toward more capable agents and eventual AGI.
IDEAS WORTH REMEMBERING
5 ideasSeveral AI verticals are already consolidating around early leaders.
In coding, customer success, and healthcare/medical scribing, Elad sees a small number of companies emerging as clear near-term winners, reducing the sense of chaos that dominated the last two years.
Large opportunity spaces remain underclaimed in sales, finance, accounting, and pharma.
Despite obvious potential for AI-driven productivity in document-heavy industries, the right product workflows and model capabilities haven’t yet crystallized, leaving room for new entrants.
Startup–startup mergers may be a rational play to beat incumbents.
Elad argues founders who are #1 and #2 in a niche should consider merging to stop fighting each other on every deal and instead consolidate resources to compete with big-platform players.
Ego, culture fears, and valuation anxiety often block sensible consolidation.
Founders and investors frequently over-index on control, status, and integration worries rather than using simple metrics (users, revenue) to structure fair deals and focus on winning larger markets.
Biotech’s structure and culture push innovation toward pharma pipelines, not new categories.
Because biotech VCs design companies to be sold into pharma’s narrow set of priorities (cancer, cardio, neuroscience), huge markets like fertility, aging, baldness, and sensory decline are relatively neglected.
WORDS WORTH SAVING
5 quotesAI is the one market in my career where I've consistently said the more I learn, the less I know.
— Elad
For the first time in like two years, it feels like some subset of things are consolidating back down.
— Elad
If I was a number one or number two in a market and I was a startup, I'd consider merging with the other party, because the real threat will be fighting the incumbents.
— Elad
People will feel like it is capitulating, but it's capitulating in service of winning.
— Sarah
Scaling up model size and training data has given us this really powerful foundation of knowledge and pattern recognition, but what people want from here is not just predicting text.
— Sarah
QUESTIONS ANSWERED IN THIS EPISODE
5 questionsHow should founders decide whether to keep competing or pursue a merger with their nearest startup rival in an AI niche?
Sarah and Elad discuss how parts of the AI market are finally consolidating, with clearer early winners emerging in areas like coding assistants, customer success, and healthcare applications. They contrast these with still-open arenas such as sales, finance, accounting, and pharma, where the right product approach or model capabilities have yet to fully materialize. Elad argues that startup–startup mergers will increasingly be rational to better fight entrenched incumbents, while Sarah highlights cultural and status barriers to such moves. The conversation then pivots to under-explored biotech opportunities and to AI research frontiers like world models and reinforcement learning as pathways toward more capable agents and eventual AGI.
What concrete product characteristics or workflows will likely differentiate eventual winners in still-open markets like sales and finance?
Given the structural incentives in biotech, what new funding or company-building models could unlock neglected areas like fertility, aging, and tooth regrowth?
How can labs practically design world models and reward structures that are rich enough to teach general problem solving without overfitting to narrow environments?
What safeguards and norms are needed as we approach technologies like cell-derived gametes, mind uploading, or direct modulation of emotions and attention?
EVERY SPOKEN WORD
Install uListen for AI-powered chat & search across the full episode — Get Full Transcript
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome